James Peyer, the CEO of Cambrian Biopharma Inc., talks about anti-aging therapies, a business model that fits the new field of geroscience. Hosted on Acast. See <a style="color: grey;" href="https://acast.com/privacy" target= "_blank" rel="noopener noreferrer">acast.com/privacy</a> for more information.

James Peyer, the CEO of Cambrian Biopharma Inc., talks about anti-aging therapies, a business model that fits the new field of geroscience. Hosted on Acast. See acast.com/privacy for more information.

James Peyer, the CEO of Cambrian Biopharma Inc., talks about anti-aging therapies, a business model that fits the new field of geroscience. Hosted on Acast. See <a href="https://acast.com/privacy" rel="noopener noreferrer">acast.com/privacy</a> for more information.

Cambrian carves out a new niche as it works to keep people from getting sick

One-on-one with medical innovators: Breakthrough medicines, billion-dollar deals, spectacular clinical successes and crushing failures all play a part in biopharma’s dynamic story. Developers make scientific advancements with the potential to change everything, only to face regulatory conundrums and ever-fluctuating markets. BioWorld tracks key events in the fast-moving sector every business day. Now, the BioWorld Insider podcast lets you hear directly from the movers and shakers whose collective work is changing how we all live. Join us for a new conversation.

Share Cambrian carves out a new niche as it works to keep people from getting sick

Sign up to save your podcasts

Cambrian carves out a new niche as it works to keep people from getting sick

Cambrian carves out a new niche as it works to keep people from getting sick